# Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

> **NCT01646320** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 320 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo matching with Dapagliflozin
- **DRUG:** Saxagliptin
- **DRUG:** Metformin immediate release (IR)

## Key facts

- **NCT ID:** NCT01646320
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2014-08
- **Final completion:** 2015-02
- **Target enrollment:** 320 (ACTUAL)
- **Last updated:** 2016-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01646320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01646320, "Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01646320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*